NCT01771146 - Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2020

Conditions

Pancreas CancerLocalized Pancreas CancerNon-metastatic Pancreas Cancer

Interventions

DRUG

FOLFIRINOX Regimen

6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion

Trial Locations (1)

75246

Baylor University Medical Center - Texas Oncology, Dallas